Clinical Trials

ACCL20N1CD: Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States

ACCL1931:   A Phase 3 Study of Sodium Thiosulfate for the Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy for Children with Medulloblastoma with Low-Risk Features

ACCL2031: A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary CNS Tumors

ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

ACNS1831: A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 Associated Low-Grade Glioma

ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib in Newly Diagnosed or Previously Untreated Low-Grade Glioma not associated with BRAFV600E Mutations or Systemic (NF1)

ACNS2021: A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation for Patients with Localized Non-Germinomatous CNS Germ Cell Tumor

AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

AGCT1532: A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors.

AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial

AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-ALL

AALL1631: International Phase 3 Trial in Philadelphia. Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

AALL1731: A Phase 3 Trial Investigating Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-ALL and the Treatment of Patients with Localized B-LLy

AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy

AALL1821: A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse

AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

AAML1921: A Phase 1/2 Study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia

AAML18P1: Stopping Tyrosine Kinase Inhibitors to Assess Treatment-Free Remission in Pediatric Chronic Myeloid Leukemia - Chronic Phase

AALL1731: A Phase 3 Trial Investigating Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-ALL and the Treatment of Patients with Localized B-LLy

AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

AHOD2131:  A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

APEC1621 SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
 
APEC1621 F: Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma.

ANBL1821: A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma.

ANBL00B1: Neuroblastoma Classification Biology Studies

APAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

APEC14B1: Project: EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

AREN03B2: Renal Tumors Classification, Biology, and Banking Study

AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

ARST2031: A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide Plus Maintenance Chemo vs Vincristine, Dactinomycin and Cyclophosphamide plus Maintenance chemo in Patients with High Risk Rhabdomyosarcoma

ARST2032:    A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

ALTE03N1: Key Adverse Events after Childhood Cancer

ALTE05N1: Umbrella Long-term Follow-up Protocol

ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer